Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism

Journal of Clinical Psychopharmacology

Volumn 19, Issue 2, 1999, Pages 149-154

  Yasui, Norio ^a   Kondo, Tsuyoshi ^a   Otani, Koichi ^b   Furukori, Hanako ^a   Mihara, Kazuo ^a   Suzuki, Akihito ^a   Kaneko, Sunao ^a   Inoue, Yoshimasa ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c Clinical Pharmacology Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; FLUNITRAZEPAM; HALOPERIDOL; ITRACONAZOLE; REDUCED HALOPERIDOL; SENNOSIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG INHIBITION; DRUG METABOLISM; DYSTONIA; FEMALE; HALLUCINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RATING SCALE; RESTLESSNESS; SCHIZOPHRENIA;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HALOPERIDOL; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032929998     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199904000-00010     Document Type: Article

References (37)

1. Tsang NM, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implication and unanswered questions. J Clin Psychopharmacol 1994;14:159-62.
2. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
3. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isoenzymes of human liver cytochrome P-450. Mephenytoirt p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985;13:443-8.
4. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991;31:655-60.
5. Llerena A, Aim C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
6. Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
7. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997;7:415-8.
8. Igarashi K, Kasuya F, Fukui M, Usuki E, Castagnoli N Jr. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following IP administration of HP. Life Sci 1995;26: 2439-46.
9. Eyles DW, McGrath JJ, Pond SM. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl) 1996;125:214-9.
10. Fang J, Baker GB, Silverstone PH, Courts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997;17:227-33.
11. Kim Y-H, Cha I-J, Shim J-C, Shin J-G, Yoon Y-R, Kim Y-K, Kim J-I, Park G-H, Jang I-J, Woo J-I, Shin S-G. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. J Clin Psychopharmacol 1996;16:247-52.
12. Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 1986;143:650-1.
13. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-90.
14. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interaction in vivo. J Clin Psychopharmacol 1996;16:104-12.
15. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for status of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 1986;73(suppl 326):1-37.
16. Lingjaerde O, Ahlfors UG, Bech P, Dencher SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 3:34):11-100.
17. Lindenmayer J-P, Bernstein-Hyman R, Grochowski S, Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 1995;28:22-31.
18. Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J Chromatogr 1989; 495:227-34.
19. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336: 529-32.
20. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metebolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
21. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 gene present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
22. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
23. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
24. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
25. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microcosms in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
26. Greenblatt DJ, von Moltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI. Interaction of triazolam and ketoconazole [letter]. Lancet 1995;345:191.
27. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microcosms in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
28. Someya T, Shibazaki M, Noguchi T, Takahashi S, Inaba T. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol 1992;12:169-74.
29. Jann MW, Lam YWF, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacology (Berl) 1990;101:107-11.
30. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abidargham A, Shoaf S, Egan M, Elkashef A, Liboff S, Linnoila M. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.
31. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl) 1986;90:468-70.
32. Miller DD, Kelly MW, Perry PJ, Coryell WH. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 1990;28:529-31.
33. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994;268:380-7.
34. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N Jr. 1-methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 1994;270:822-30.
35. Schotte A, Bonaventure P, Janssen PFM, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 1995;69:399-112.
36. Bowen WD, Moses EL, Tolentino PJ, Walker JM. Metabolism of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptors. Eur J Pharmacol 1990;177:111-8.
37. Lane HY, Lin HN, Hu OYP, Chen CC, Jann NW, Chang WH. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:299-311.